**Abstract**

**Objective of Study:** To investigate whether indoleamine 2,3-dioxygenase 1 (IDO1) mediated L-tryptophan (TRP)-kynurenine (KYN) pathway metabolism plays a critical role in depressive symptoms occurring as a side effect of interferon (IFN)-α therapy, we measured the levels of TRP metabolites in serum of hepatitis C vial (HCV) patients. To investigate whether depression-like behavior is affected by IFN-γ treatment, we transfected pCpG-Muγ plasmid, continuously expressing murine IFN-γ, to normal mice and IDO1-gene deficient (K.O.) mice.

**Methods:** We measured the levels of TRP metabolites in serum of HCV patients with and without depression symptom during IFN-α therapy using by HPLC. For the animal model, C57BL/6J mice and IDO1 K.O. mice were transfected with murine IFN-γ expressing plasmid by a hydrodynamic tail vein injection.

**Summary of results:** In serum of HCV patients, the levels of TRP metabolites were significantly changed. Especially, the increase in serum 3-hydroxykynurenine (3-HK) concentration in depressive HCV patients was much larger than that in HCV patients without depressive symptoms. The ratios of serum KYN/TRP, reflecting IDO1 activity, and 3-HK/kynurenic acid (KA) were increased in depressive and non-depressed HCV patients with therapy but the increases in serum KYN/TRP and 3-HK/KA ratios in depressive patients disappeared completely after the end of the therapy. When pCpG-Muγ was transfected to normal mice, depression-like behavior was significantly increased. Additionally, IFN-γ gene transfer to mice caused a dramatically changes of TRP metabolites concentrations in serum, as same as HCV patients. On the other hand, genetic deletion of IDO1 abrogated the increase depressive-like behavior after IFN-γ gene transfer.

**Conclusions:** Our results indicate that the KYN pathway of IDO1-mediated TRP metabolism plays a critical role in depressive symptoms associated with IFN
